Evgeny E. Zvonkov — Head of the Division of Lymphoproliferative Diseases, Head of the Department of Hematology and Lymphoma Chemotherapy with Bone Marrow andHematopoietic Stem Cell Transplantation Unit, hematologist, Doctor of Medical Sciences
Evgeny Zvonkov graduated from the Far Eastern State Medical University with a degree in general medicine in 1997. He completed his clinical postgraduate studies in the specialty “Hematology and Blood Transfusion” in the Department of Chemotherapy of Hematological Diseases and Intensive Care of the Hematological Research Center of the Russian Academy of Medical Sciences (1999 – 2002). He defended his Candidate of Medical Sciences thesis on the topic, “Primary lymphatic tumors of the stomach” and doctoral thesis on “Primary extranodal B-cell lymphatic tumors: clinic, diagnosis, treatment” (2009).
He has been the head of the Department of Hematology and Lymphoma Chemotherapy with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit since 2014.
Zvonkov's scientific and therapeutic work covers the study of the molecular, cytogenetic, and morphological foundations of aggressive B and T cell lymphomas, including primary diffuse large B-cell lymphoma of the CNS, mantle cell lymphoma, follicular lymphoma, marginal zone cell lymphoma, and Waldenstrom's macroglobulinemia in order to identify molecular and biological markers for the improvement of diagnostics, for adequate selection of differential therapy and disease monitoring, and for the study of the role of oncogenic mutations in the prognosis of lymphoproliferative diseases.
Zvonkov is an active participant in numerous congresses and conferences both as a speaker and a moderator of scientific events, including in 10 international conferences (poster reports – 9, oral report, China, 2019).
He is a member of the Problem Commission “Clinical Research in Hematology (Hemoblastosis; Hematopoiesis Depression; HSCT; Myelo- and lymphoproliferative diseases; Tumors of the lymphatic system; Pathology of red blood; ITP; Porphyria), transfusiology, pathology of hemostasis, surgical hematology, anesthesiology and intensive care.”
Since 2013, he has been a member of the Academic Council and is also a member of the Dissertation Council Д 208.135.01. In 2016, he was awarded a certificate of merit from the Ministry of Health of the Russian Federation for services in the field of healthcare and many years of conscientious work. In 2017, he was awarded the highest medical category. Since 2018, he has been a member of the Editorial Board of the scientific publication “Hematology and Transfusiology,” and since 2022, a member of the Expert Council of the Higher Attestation Commission. In 2023, for many years of fruitful work, professional skills and high personal achievements in the field of healthcare, he was awarded the badge “Excellent Healthcare Worker” (Order of the Ministry of Health of the Russian Federation No. 634-п dated 26.07.2023).
In 2022, Evgeny Zvonkov became the head of the Division of Lymphoproliferative Diseases, which is comprised of 3 departments, each of which has its own direction within the general topic of diagnosis and treatment of a wide range of lymphoproliferative diseases.
Under his guidance, more than 20 clinical residents have completed clinical residency and 4 dissertations for the degree of Candidate of Medical Sciences have been defended. Currently, he is a consultant for 3 dissertation works for the degree of Doctor of Medical Sciences and 4 more doctoral works are planned for the future.
In 2017, under the leadership of E.E. Zvonkov, the clinical trial “Method for improving the effectiveness of programmatic chemotherapy for primary diffuse large B-cell lymphoma of the central nervous system” was developed and conducted. He was also one of the developers of the clinical trials “Improving the effectiveness of induction therapy for patients with Waldenstrom's macroglobulinemia - the use of a Bruton tyrosine kinase inhibitor in combination with immunochemotherapy” in 2019 and “Mosunetuzumab monotherapy in adult patients with recurrent/refractory follicular lymphoma (C82) who received 2 or more lines of therapy to increase the effectiveness of treatment with the aim of improving long-term results compared to standard immunochemotherapy” in 2024.
Under his leadership, 35 local recommendations for the treatment of B- and T-cell lymphoproliferative diseases were developed and updated in 2024. E.E. Zvonkov was included in the working groups for the development of Russian Clinical Recommendations for the diagnosis and treatment of B-cell lymphoproliferative diseases and Waldenstrom macroglobulinemia, approved in 2024.
Since 2024, he has been a co-researcher in two clinical trials on CAR T-cell therapy: HemC101-01-01, “An Extension Study to Assess the Safety and Efficacy of an Anti-CD19 CAR-T Drug in Patients with B-cell Lymphoproliferative Disorders” and HemC101-01-02 “Open Non-interventional Single-group Follow-up Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Drug in Patients with B-cell Lymphoproliferative Disorders.”
In 2024, E.E. Zvonkov received the patent “Treatment Method for Patients with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System” RU 2831407 C1.
His total length of service is 26 years, 15 of which are after being awarded the degree Doctor of Medical Sciences. In the period from 2001 to 2025, he has published 442 publications (107 scientific articles and 315 abstracts), including in Russian and foreign scientific publications. There are 102 publications in journals indexed in recognized international citation systems (bibliographic databases) in relevant fields of science.
Hirsch Index according to RSCI–16. Hirsch Index for Scopus–4. The Hirsch Index for Web of Science–5.
